GLUC — Glucose Health Share Price
- $1.54m
- $1.23m
- $0.95m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.99 | ||
Price to Tang. Book | 2 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.38 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -45.81% | ||
Return on Equity | -264.22% | ||
Operating Margin | -31.99% |
Financial Summary
Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0 | 0 | 0.31 | 0.48 | 0.95 | n/a | n/a | 433.82% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Glucose Health, Inc. is engaged in the development of soluble fiber nutrition products formulated to support good metabolic health. The Company manufactures and distributes nutritional beverages under the GLUCODOWN registered trademark. Its niche is the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. The Company’s GlucoDown brand predominantly serves diabetic and pre-diabetic consumers, offering a functional beverage choice versus other sugar-free beverages. GlucoDown is an iced tea mix beverage infused with soluble fiber, launched in North America. GlucoDown brand has eight flavor variations and two packaging formats. The Company’s FIBER UP brand serves health-conscious consumers, particularly those 45 and over, offering a ready-to-drink beverage with nutritional benefits.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- March 27th, 2007
- Public Since
- July 11th, 2008
- No. of Employees
- 2
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 17,061,965

- Address
- 609 SW 8TH STREET, SUITE 600, BENTONVILLE, 72712
- Web
- https://www.glucosehealthinc.com/
- Phone
- +1 4798023827
- Auditors
- Fruci & Associates II,PLLC
Upcoming Events for GLUC
Similar to GLUC
Adia Nutrition
Pink Sheets on Nasdaq
African Agriculture Holdings
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
FAQ
As of Today at 20:52 UTC, shares in Glucose Health are trading at $0.09. This share price information is delayed by 15 minutes.
Shares in Glucose Health last closed at $0.09 and the price had moved by -82.04% over the past 365 days. In terms of relative price strength the Glucose Health share price has underperformed the S&P500 Index by -83.03% over the past year.
There is no consensus recommendation for this security.
Find out moreGlucose Health does not currently pay a dividend.
Glucose Health does not currently pay a dividend.
Glucose Health does not currently pay a dividend.
To buy shares in Glucose Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.09, shares in Glucose Health had a market capitalisation of $1.54m.
Here are the trading details for Glucose Health:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GLUC
Based on an overall assessment of its quality, value and momentum Glucose Health is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glucose Health. Over the past six months, its share price has underperformed the S&P500 Index by -62.57%.
As of the last closing price of $0.09, shares in Glucose Health were trading -64.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Glucose Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Glucose Health's management team is headed by:
- Murray Fleming - CEO
- Peggy Knight - CMO
- John Fieldly - DRC